News 24.10.2017 Neurimmune announced today that it has raised $150 million to fund its growth strategy. The financing will accelerate the development of Neurimmune's human antibody pipeline through clinical proof of concept. Neurimmune receives a one-time $150 million payment from its collaboration partner Biogen in exchange for a 15% reduction in the previously...
External events
Event date: 27.09.2017
You plan to protect and use your invention without getting a patent. You want to protect and sell your product without registering your brand or design. What options are available? How are these implemented? It is important to protect intellectual property. This is usually done through patents, trademarks, designs and...
News 30.08.2017 Biogen (NASDAQ: BIIB) announced results from a recently conducted analysis of the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company’s investigational treatment for early Alzheimer’s disease. The updated analyses include data from the placebo-controlled period and LTE for patients treated with aducanumab up to 24...
News 28.08.2017 Virometix today announced that it has raised CHF 1.2 million from new shareholders in an extension to its recent Series A financing round. The additional funds will be used to further speed up development of its vaccine candidates for RSV and cancer immunotherapy. Furthermore, the company announced the appointment of...
External events
Event date: 28.09.2017
The purpose of the event is to show Swiss companies what the European research area is doing in the area of laboratory fields of technology and how Swiss companies can participate in these research programs.
Venue: Kongress + Kursaal Bern AG, Kornhausstrasse 3, 3000 Bern 22
More information